Core Insights - Bionano Genomics reported a decrease in total revenue for Q4 2025 and full year 2025, with total revenue of $8.0 million for Q4, down 3% from $8.2 million in Q4 2024, and $28.5 million for the full year, down 7% from $30.8 million in 2024 [4][21]. Financial Performance - Q4 2025 saw consumables and software revenues decrease by 1%, while instrument revenue slightly declined from $2.8 million in Q4 2024 to $2.7 million in Q4 2025 [4]. - The company sold 7,554 nanochannel array flowcells in Q4 2025, a 6% decrease from 8,058 flowcells sold in Q4 2024 [4]. - The installed base of OGM systems increased by 4% to 387 at the end of Q4 2025, up from 371 at the end of Q4 2024 [4]. - Gross margin improved to 43% in Q4 2025 from 42% in Q4 2024, with non-GAAP gross margin also at 43% [4]. - Operating expenses were reduced by 22% to $11.9 million in Q4 2025, and non-GAAP operating expenses decreased by 9% to $9.7 million [4]. Business Highlights - The company noted a 47% increase in the Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies, effective in 2026 [2][10]. - Bionano Symposium 2026 showcased advances in OGM, with nearly 40 presentations highlighting its applications in various fields, including hematologic malignancies and oncology research [10]. - The company reported 136 peer-reviewed publications in Q4 2025, indicating growing acceptance of OGM as a cytogenetic standard [10]. - Bionano initiated revenue guidance for Q1 2026 in the range of $6.5 to $6.7 million and for the full year 2026 in the range of $30 to $33 million [10]. Cash Position - As of December 31, 2025, Bionano ended the year with cash, cash equivalents, and available-for-sale securities totaling $29.6 million [4].

Core Insights - Bionano Genomics showcased advancements in optical genome mapping (OGM) during Symposium 2026, emphasizing its potential for scaling up to thousands of samples per year through automation and advanced software solutions [1][2][10] Group 1: Symposium Highlights - The event attracted over 1,250 registrants and featured 35 speakers, highlighting the community's engagement and the advancements in OGM technology [2] - Dr. Alexander Hoischen from Radboud University Medical Center emphasized 2026 as a pivotal year for scaling OGM, aiming to process 3,000 samples annually, up from 500 in 2025 [3] - Dr. Chantal Courtemanche presented a protocol for purifying DNA and RNA from FFPE samples using Bionano's Ionic system, which enhances the quality of next-generation sequencing (NGS) assays [4] Group 2: Technological Innovations - Dr. Vineet Bafna introduced a computational tool called OMKar for generating digital karyotypes from complex chromosomal rearrangements, which could enhance future software developments [5] - Dr. Brandon Shaw demonstrated how VIA software supports the analysis of OGM data, facilitating consistent assessments of structural variants in hematologic malignancies [6][7] - Dr. Adam Smith discussed the scalability of OGM, noting that it could process up to 10,000 samples per year, significantly outperforming long-read sequencing systems in terms of throughput and cost [10] Group 3: Community and Future Directions - The International OGM Consortium (ICOGM) was introduced to foster collaborative research efforts in OGM [11] - The final day of the symposium concluded with discussions on best practices for OGM implementation and future research directions in cytogenomics and molecular pathology [12] - Bionano's leadership highlighted the transformative role of OGM in advancing cytogenomics and molecular pathology, reinforcing the community's commitment to innovation [15][17]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 921 ...

Core Viewpoint - Bionano Genomics is focusing on routine users of its optical genome mapping (OGM) systems and VIA™ software to drive revenue and gross profit, achieving a gross margin above 50% in Q2 2025, indicating a successful strategy shift [2][4]. Financial Results - Total revenue for Q2 2025 was $6.7 million, a decrease of 13% from $7.8 million in Q2 2024, primarily due to the discontinuation of clinical services [4]. - Consumables and software revenues increased by 16% compared to the prior year [4]. - Instrument revenue decreased from $2.3 million in Q2 2024 to $1.4 million in Q2 2025, reflecting the company's strategy to focus on routine users rather than new instrument placements [4]. - Adjusted for instrument sales and discontinued clinical services, combined revenue for consumables, software, and remaining services increased by 11% [4]. - The company sold 7,233 nanochannel array flowcells in Q2 2025, a 17% increase from 6,165 flowcells sold in Q2 2024 [4]. - Gross margin was 52% in Q2 2025, up from 33% in Q2 2024 [4][18]. - Operating expenses were reduced by 42% to $11.3 million, with non-GAAP operating expenses down by 53% to $8.8 million [4]. Business Highlights - The installed base of OGM systems increased by 4% to 378 at the end of Q2 2025 [4]. - The company achieved a record of 119 peer-reviewed publications, showcasing the growing utilization of OGM [4]. - Bionano announced upgrades to its VIA and Solve™ software, enhancing genomic data analysis capabilities [4]. - The American Medical Association established a second Category I CPT code for OGM use in cytogenomic genome-wide analysis [4]. 2025 Outlook - The company anticipates Q3 2025 revenue in the range of $6.7 to $7.2 million and full-year 2025 revenue between $26.0 to $30.0 million [11]. - Expectations for new OGM installations have been increased to 20 to 25 for the full year 2025 [11]. - The company ended Q2 2025 with cash and equivalents totaling $27.4 million, providing a cash runway into the first quarter of 2026 [4][11].